Literature DB >> 9917581

Mirtazapine: a newer antidepressant.

P M Hartmann1.   

Abstract

Mirtazapine is a newer antidepressant that exhibits both noradrenergic and serotonergic activity. It is at least as effective as the older antidepressants for treating mild to severe depression. Sedation is the most common side effect. Although agranulocytosis is the most serious side effect, it is rare (approximately one in 1,000) and usually reversible when the medication is stopped. Mirtazapine is relatively safe in overdose. Many clinicians consider mirtazapine a second-line or even third-line antidepressant to be used when older antidepressants are not tolerated or are ineffective. Physicians who are concerned about the risks of elevated lipid levels and agranulocytosis may choose to reserve mirtazapine as a third-line choice. It is particularly useful in patients who experience sexual side effects from other antidepressants. Mirtazapine is also a good choice in depressed patients with significant anxiety or insomnia. Although mirtazapine has been used successfully in Europe for a number of years, its place in the care of patients with depression in the United States has not yet been established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9917581

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  8 in total

Review 1.  Psychological Considerations in Hematopoietic Stem Cell Transplantation.

Authors:  Hermioni L Amonoo; Christina N Massey; Melanie E Freedman; Areej El-Jawahri; Halyna L Vitagliano; William F Pirl; Jeff C Huffman
Journal:  Psychosomatics       Date:  2019-02-14       Impact factor: 2.386

Review 2.  Mirtazapine adjunct for people with schizophrenia.

Authors:  Luke A Perry; Dhruvesh Ramson; Suzanne Stricklin
Journal:  Cochrane Database Syst Rev       Date:  2018-05-26

3.  Effect of Mirtazapine on Gastric Emptying in Patients with Cancer-associated Anorexia.

Authors:  N Kumar; Sukanta Barai; S Gambhir; N Rastogi
Journal:  Indian J Palliat Care       Date:  2017 Jul-Sep

4.  A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.

Authors:  Alireza Khalilian; Davoud Ahmadimoghaddam; Shiva Saki; Younes Mohammadi; Maryam Mehrpooya
Journal:  Biopsychosoc Med       Date:  2021-02-03

5.  Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report.

Authors:  Janelle Y Gooden; Paul Y Takahashi
Journal:  J Med Case Rep       Date:  2013-02-06

6.  Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice.

Authors:  Tamara Bittolo; Carlo Antonio Raminelli; Chiara Deiana; Gabriele Baj; Valentina Vaghi; Sara Ferrazzo; Annalisa Bernareggi; Enrico Tongiorgi
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

7.  Mirtazapine Induced Akathisia: Understanding a Complex Mechanism.

Authors:  Dhanya Raveendranathan; Gopal Rao Swaminath
Journal:  Indian J Psychol Med       Date:  2015 Oct-Dec

8.  Protective role of mirtazapine in adult female Mecp2+/- mice and patients with Rett syndrome.

Authors:  Javier Flores Gutiérrez; Claudio De Felice; Giulia Natali; Silvia Leoncini; Cinzia Signorini; Joussef Hayek; Enrico Tongiorgi
Journal:  J Neurodev Disord       Date:  2020-09-28       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.